Perrigo acquires generic Retin-A portfolio
Ireland-incorporated Perrigo (NYSE: PRGO) has said it will acquire a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, a subsidiary of Rouses Point Pharmaceuticals.
Perrigo, which has just escaped from a hostile takeover battle with Mylan (The Pharma Letter November 13), was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. Generic and brand sales of Retin-A, which is indicated for the topical treatment of acne vulgaris, were around $287 million for the 12-months ending October 2015. Additional financial terms were not disclosed.
The company has recently zoned in on acquisitions of generic pharmaceuticals, including Entocort (budesonide), which it agreed to acquire for Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) just last month for $380 million (The Pharma Letter November 23).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze